Cargando…

The other possible mechanism of the benefits of RAAS inhibition in the athogenesis of COVID‐19

Detalles Bibliográficos
Autores principales:	Gupta, Neelesh, Patel, Krunalkumar, Gupta, Rajeev
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wiley Periodicals, Inc. 2020
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724212/ https://www.ncbi.nlm.nih.gov/pubmed/33174213 http://dx.doi.org/10.1002/clc.23494

Ejemplares similares

A word of caution
por: Gupta, Neelesh, et al.
Publicado: (2020)

RAAS-Blockade in COVID-19: The Ace of Spades?
por: Agarwal, Krishna A., et al.
Publicado: (2021)

Underlying Coronary Microvascular Disease May Lead to Underestimation of Global Longitudinal Strain Differences
por: Gupta, Neelesh, et al.
Publicado: (2021)

The influence of renin angiotensin aldosterone system (RAAS), endothelial nitric oxide synthase (eNOS) and erythropoietin (EPO) on COVID-19 complications
por: Papadopoulos, Konstantinos I., et al.
Publicado: (2022)

RAAS inhibition and mortality in hypertension
por: Ferrari, Roberto
Publicado: (2013)

Dysgeusia in COVID-19: Possible Mechanisms and Implications
por: Lozada-Nur, Francina, et al.
Publicado: (2020)

Human pluripotent stem cell-derived functional sympathetic neurons express ACE2 and RAAS components: a framework for studying the effect of COVID-19 on sympathetic responsiveness
por: Wu, Hsueh-Fu, et al.
Publicado: (2022)

Comparison of Severity of COVID-19 Infection among Patients Using RAAS Inhibitors and Non-RAAS Inhibitors
por: Reddy, Paidi Ramakrishna, et al.
Publicado: (2021)

RAAS INHIBITORS ARE CARDIOPROTECTIVE IN PATIENTS WITH COVID-19
por: Holmes, Adam R., et al.
Publicado: (2021)

Hyperglycemia and the novel Covid-19 infection: Possible pathophysiologic mechanisms
por: Ilias, Ioannis, et al.
Publicado: (2020)

Wise investment is needed for maximising the benefits in Covid times
por: Gupta, Harish, et al.
Publicado: (2022)

RAAS inhibition and beyond—cardiovascular medications in patients at risk of or affected by COVID-19
por: Dutsch, Alexander, et al.
Publicado: (2023)

A proposed mechanism for the possible therapeutic potential of Metformin in COVID-19
por: Esam, Zohreh
Publicado: (2020)

RAAS inhibitors do not increase the risk of COVID-19
por: Fernández-Ruiz, Irene
Publicado: (2020)

COVID-19 and RAAS inhibitors: is there a final conclusion?
por: Talebi-Taher, Mahshid, et al.
Publicado: (2021)

RAAS inhibitors in COVID-19: not all are created equal!
por: Kow, Chia Siang, et al.
Publicado: (2023)

Fiberoptic bronchoscope assisted difficult airway management in maxillofacial trauma
por: Agrawal, Pramendra, et al.
Publicado: (2011)

Progressive cholangiopathy in COVID-19 patients: Other possible diagnoses than ketamine-induced cholangiopathy should be considered
por: Deltenre, Pierre, et al.
Publicado: (2021)

Possible role of diabetes and related mechanisms in COVID-19-induced cognitive impairment
por: Wang, Shenglin, et al.
Publicado: (2022)

Is it possible to eradicate the covid-19 or not?
por: Khezri, Rozhan, et al.
Publicado: (2022)

Reply to: “Progressive cholangiopathy in COVID-19 patients: Other possible diagnoses than ketamine-induced cholangiopathy should be considered”
por: Mallet, Vincent
Publicado: (2021)

The Role of Systolic Blood Pressure Reduction in Diastolic Dysfunction: RAAS Inhibition versus Non-RAAS Blood Pressure Lowering
por: Park, Sung-Ji
Publicado: (2020)

Diagnostic accuracy and utility of SARS-CoV-2 antigen lateral flow assays in medical admissions with possible COVID-19
por: Houston, H., et al.
Publicado: (2021)

Meta-analysis: RAAS inhibitors and COVID-19 positivity and/or mortality
Publicado: (2020)

COVID-19 and the RAAS—a potential role for angiotensin II?
por: Busse, Laurence W., et al.
Publicado: (2020)

RAAS, ACE2 and COVID-19; a mechanistic review
por: Elshafei, Ahmed, et al.
Publicado: (2021)

Reply to: RAAS inhibitors in COVID-19: not all are created equal!
por: Gonçalves, Jorge, et al.
Publicado: (2023)

Azygos vein thrombosis in COVID-19
por: Chandrakar, Saurabh, et al.
Publicado: (2022)

Repurposing fluvoxamine, and other psychiatric medications, for COVID‐19 and other conditions
por: Lenze, Eric J., et al.
Publicado: (2022)

Will COVID-19 vaccine equity be possible in India?
por: Mathivathanan, Kanagavalli
Publicado: (2021)

Possible agent for COVID-19 treatment: Rifampicin
por: Aydin, Ozlem Celik, et al.
Publicado: (2022)

Chronic renal insufficiency among Asian Indians with type 2 diabetes: I. Role of RAAS gene polymorphisms
por: Prasad, Pushplata, et al.
Publicado: (2006)

Covid-19-induced coagulopathy and observed benefits with anticoagulation
por: Karimzadeh, Sedighe, et al.
Publicado: (2020)

COVID-19 and Alcohol Consumption: No Preventive or Therapeutic Benefits
por: Shrivastava, Saurabh RamBihariLal, et al.
Publicado: (2020)

Antenatal corticosteroids and COVID-19: balancing benefits and harms
por: Liauw, Jessica, et al.
Publicado: (2020)

Acute Abdomen in a Child following Abrupt Withdrawal of Imipramine - A Case Report
por: Gupta, Rajeev
Publicado: (1989)

Hypomania following Abrupt Lithium withdrawal
por: Gupta, Rajeev
Publicado: (1987)

Caffeinism in Chronic Schizophrenic Patients
por: Gupta, Rajeev
Publicado: (1985)

The RAAS Goodfellas in Cardiovascular System
por: Caputo, Ilaria, et al.
Publicado: (2023)

The interaction of RAAS inhibitors with COVID-19: Current progress, perspective and future
por: Zhang, Jishou, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lui87jgnjsrdgalkk4t3tln31s